^
    Back
    Association details:
    Biomarker:SEMA6A overexpression + BRAF mutation
    Cancer:Melanoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Tafinlar (dabrafenib) (BRAF inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    J Exp Clin Cancer Res
    Title:

    SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma

    Published date:
    04/19/2022
    Excerpt:
    Finally, in BRAF-mut melanoma patients treated with dabrafenib+trametinib, high SEMA6A predicts shorter recurrence-free interval....Overall, our results indicate that SEMA6A contributes to microenvironment-coordinated evasion of melanoma cells from dual BRAF/MEK inhibition and it might be a good candidate predictor of short-term benefit from dual BRAF/MEK inhibition.
    DOI:
    10.1186/s13046-022-02354-w